<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01761981</url>
  </required_header>
  <id_info>
    <org_study_id>1900</org_study_id>
    <nct_id>NCT01761981</nct_id>
  </id_info>
  <brief_title>Institutional Registry of Haemorrhagic Hereditary Telangiectasia</brief_title>
  <official_title>Institutional Registry of Haemorrhagic Hereditary Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to create an institutional and population-based registry of
      Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological
      data, risk factors, diagnosis, prognosis, treatment, monitoring and survival.

      This study will also describe the occurrence of Haemorrhagic Hereditary Telangiectasia in the
      population of HIBA in the Central Hospital, as well as the characteristics of clinical
      presentation and evolution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Haemorrhagic Hereditary Telangiectasia is a uncommon autosomic hereditary disorder
      caracterizad for recurrent epistaxis,cutaneomucous telangiectasias and arteriovenous
      malformations in diferent organs; brain, lung, liver and gastrointestinal are more often
      afected . Afect one in 5000-8000 individual in worldwide. HHT may produce important morbidity
      like brain absces, stroke, hemoptisis and cronic ferropenic anemia.

      Molecular mechanism of this disorder are complex and still no fully dilucidated. The genes
      mutated in HHT encode endothelial cell-expressed proteins that mediate signalling by the
      transforming growth factor (TGF)b superfamily. Endoglin (HHT type I) and ACVRL-1 (HHT type 2)
      mutations are responsible in more than 80% of the individuals. Mutation of SMAD 4 protein
      (MADH4)cause HHT in association with juvenile polyposis. HHT may associated with primary
      pulmonary hypertension en more rare cases.

      There arent HHT register in Argentina and Latinamerican population. This registry may gader
      valious information in order to generate a better diagnosis and treatment of our population
      and others.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>morbidity</measure>
    <time_frame>1 year</time_frame>
    <description>Control visit every three month</description>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Haemorrhagic Hereditary Telangiectasia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Haemorrhagic Hereditary Telangiectasia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with HHT defined.

          2. Followed in Unidad HHT of Hospital Italiano de Buenos Aires.

        Exclusion Criteria:

        1. Denied to participated in the registry or inform consent process.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo M Serra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HHT Center of Excelence Hospital Italiano de Buenos Aires</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcelo M Serra, MD</last_name>
    <phone>+541149590200</phone>
    <phone_ext>4419</phone_ext>
    <email>marcelo.serra@hospitalitaliano.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diego H Giunta, MD</last_name>
    <phone>+541149590200</phone>
    <phone_ext>4419</phone_ext>
    <email>diego.giunta@hospitalitaliano.org.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1081</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo M Serra, MD</last_name>
      <phone>+541149590200</phone>
      <phone_ext>4419</phone_ext>
      <email>marcelo.serra@hospitalitaliano.org.ar</email>
    </contact>
    <contact_backup>
      <last_name>Diego H Giunta, MD</last_name>
      <phone>+541149590200</phone>
      <phone_ext>4419</phone_ext>
      <email>diego.giunta@hospitalitaliano.org.ar</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <last_update_submitted>December 16, 2015</last_update_submitted>
  <last_update_submitted_qc>December 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Diego Hernan Giunta, MD</investigator_full_name>
    <investigator_title>Marcelo Martin Serra</investigator_title>
  </responsible_party>
  <keyword>Haemorrhagic Hereditary Telangiectasia</keyword>
  <keyword>Rendu Osler Weber Syndrome</keyword>
  <keyword>Osler Weber Rendu Syndrome</keyword>
  <keyword>HHT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

